KALEIDO BIOSCIENCES INC - KLDO STOCK NEWS

Kaleido Biosciences (Nasdaq: KLDO) announced a public offering of 5,250,000 shares at $11.50 each, potentially raising approximately $60.4 million. Underwriters also have a 30-day option for an additional 787,500 shares. The offering, managed by Morgan Stanley and Piper Sandler, is set to close on February 8, 2021. Proceeds will fund ongoing clinical studies for KB109 and KB295, additional research initiatives, and general corporate purposes. The offering is registered under Form S-3 and will comply with customary closing conditions.

Kaleido Biosciences (Nasdaq: KLDO) announced a public offering of $50 million in common stock, with an additional $7.5 million option for underwriters. The funds will support clinical studies of KB109 for COVID-19 and KB295 for ulcerative colitis, along with other R&D activities. Morgan Stanley and Piper Sandler are managing the offering. Completion timing and final terms remain uncertain. This offering aims to enhance Kaleido's research efforts and potential commercialization initiatives as they explore new treatments targeting various diseases.

Kaleido Biosciences (Nasdaq: KLDO) announced that Chief Scientific Officer Johan van Hylckama Vlieg, Ph.D., will present at the Keystone Symposium at 12:15 p.m. MST today. The presentation will cover updates on the Kaleido MMT^TM platform and interim data from the K031 COVID-19 study, highlighting the effects of KB109 on symptom resolution in mild-to-moderate COVID-19 patients. Positive interim results indicated KB109's potential benefits in improving immune function through microbiome modulation, especially in patients with comorbidities.

Kaleido Biosciences (Nasdaq: KLDO) announced positive interim results from the K031 clinical study, showing that its MMT candidate, KB109, is well tolerated in outpatients with mild to moderate COVID-19. The preliminary analysis of 176 patients revealed no unexpected adverse events and indicated a median symptom resolution time of 18 days with KB109 compared to 27 days with supportive care alone for patients with comorbidities. The full study with 350 patients is fully enrolled, with results expected in Q1 2021, reinforcing the potential clinical benefit of KB109 in treating COVID-19.

Kaleido Biosciences announced a presentation by CEO Dan Menichella at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 2:00 p.m. EST. A live audio webcast will be available on their website, with an archived replay to follow. Kaleido is a clinical-stage healthcare company focused on Microbiome Metabolic Therapies (MMT™) aimed at addressing unmet health needs through innovative treatments. For more details, visit their site.

Kaleido Biosciences (Nasdaq: KLDO) announced the completion of enrollment for its clinical study K031, which involves 350 subjects to evaluate the Microbiome Metabolic Therapy (MMT™) candidate KB109 for mild-to-moderate COVID-19 treatment. The study aims to assess KB109's effectiveness combined with supportive self-care for symptomatic patients. Topline results are expected in Q1 2021. Kaleido emphasizes KB109's potential to boost immune response through microbiome modulation, underlining its largest study to date as a pivotal step in the clinical development of MMT candidates.

Kaleido Biosciences (KLDO) announced that CEO Dan Menichella will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference from November 30 to December 3, 2020. The session will be accessible to registered attendees via the conference site until December 3 and will also be available on Kaleido's Investors & Media page starting November 30. Kaleido focuses on microbiome-based therapies and has a pipeline targeting significant unmet medical needs. An archived replay of the presentation will be available for 90 days post-event.

Kaleido Biosciences, Inc. (Nasdaq: KLDO) reported a net loss of $23.1 million for Q3 2020, equating to $0.65 per share, compared to a loss of $22.0 million in Q3 2019. Research and development expenses slightly decreased to $15.7 million, while general and administrative costs rose to $7.2 million, primarily due to stock option modifications. The company continues its COVID-19 program with KB109, expecting topline data in Q1 2021. Kaleido holds $54.5 million in cash with a runway into the second half of 2021, aiming to advance its Microbiome Metabolic Therapy pipeline across various diseases.

Kaleido Biosciences (Nasdaq: KLDO) announced that data from its Microbiome Metabolic Therapy (MMT™) programs will be presented at IDWeek 2020 and The Liver Meeting 2020. Specifically, candidate KB109, under study for mild-to-moderate COVID-19, will be showcased at IDWeek from Oct. 21-25, 2020. Additionally, results for KB39 and KB174 will be presented at the AASLD meeting on Nov. 13-16, 2020. These studies highlight the candidates' potential in treating infections, liver disease, and cardiovascular conditions, showcasing significant metabolic benefits and microbiome modulation.